Harmony Biosciences Holdings (HRMY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.94B
Last updated: Nov 17, 2026 at 4:15 PM ET
Harmony Biosciences Holdings (HRMY) Statistics
Harmony Biosciences Holdings (HRMY) has a market cap of $1.94B and an enterprise value of $1.44B. It holds $498.00M more cash than debt, 25.73% of its market cap.
Total Valuation
Enterprise value is 25.73% below the market cap, as cash exceeds debt.
| Market Cap | $1.94B |
|---|---|
| Enterprise Value | $1.44B |
| Latest price (Nov 17, 2026) | $32.96 |
Key Dates
| Last Earnings Date | Nov 4, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.9x and 1.8x. Its year-end P/E ranged from 8.5x to 51.4x from 2021 to 2025.
| P/E Ratio | 9.6x |
|---|---|
| Forward P/E | 8.6x |
| P/S Ratio | 1.9x |
| Forward P/S | 1.9x |
| P/B Ratio | 1.8x |
| P/TBV Ratio | 1.9x |
| P/OCF Ratio | 6.0x |
| PEG Ratio | 1.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 5.9x EBITDA.
| EV / Earnings | 8.0x |
|---|---|
| EV / Sales | 1.5x |
| EV / EBITDA | 5.9x |
Price Statistics
The stock is down 3.88% over 52 weeks and trades 14.30% below its 50-day average.
| Beta (1Y) | 0.64 |
|---|---|
| 52-Week Change | -3.88% |
| 1-Month Change | -13.15% |
| 3-Month Change | -15.12% |
| 6-Month Change | +10.49% |
| 5-Year Change | -6.53% |
| Total Return (1Y) | -3.88% |
| Total Return (3Y CAGR) | +6.92% |
| Total Return (5Y CAGR) | -3.39% |
| Return vs SPY (1Y) | -14.59% |
| Max Drawdown (1Y) | -34.49% |
| Max Drawdown (3Y) | -37.58% |
| Sharpe Ratio (1Y) | -0.08 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $38.46 |
| 200-Day Average | $34.55 |
| 52-Week Range | $25.90 to $43.49 |
| RSI (14 Days) | 33.5 |
| Average Volume (20 Days) | 1.20M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.44x current liabilities, and total debt is 0.14x shareholder equity.
| Current Ratio | 3.44x |
|---|---|
| Quick Ratio | 3.42x |
| Debt / Equity | 0.14x |
| Debt / EBITDA | 0.62x |
| Interest Coverage | 16.95x |
Returns and Efficiency
Return on invested capital is 13.73% over the last 12 months, against a 5-year average of 19.07%.
| Return on Equity (ROE) | 16.66% |
|---|---|
| Return on Assets (ROA) | 12.08% |
| Return on Invested Capital (ROIC) | 13.73% |
| ROE (5Y Average) | 26.30% |
| ROA (5Y Average) | 15.57% |
| ROIC (5Y Average) | 19.07% |
| Asset Turnover | 0.74x |
| Inventory Turnover | 42.01x |
| Receivables Turnover | 8.29x |
| Cash Conversion Cycle | 18 days |
Taxes
Income tax took 23.33% of pretax income over the last 12 months.
| Income Tax (TTM) | $54.36M |
|---|---|
| Effective Tax Rate | 23.33% |
Scores
HRMY has an Altman Z-Score of 4.84, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.84 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $989.36M over the last 12 months is up 19.79% from the 12 months before.
| Revenue | $989.36M |
|---|---|
| Revenue Growth (YoY) | +19.79% |
| Gross Profit | $732.42M |
| Operating Income | $219.36M |
| Pretax Income | $232.96M |
| Net Income | $178.60M |
| EBITDA | $241.59M |
| Reported EPS (TTM) | $3.45 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.30% of the $1.48B in total assets.
| Cash and Equivalents | $647.10M |
|---|---|
| Total Debt | $149.10M |
| Net Cash | $498.00M |
| Net Cash Per Share | $8.53 |
| Working Capital | $663.29M |
| Shareholder Equity | $1.07B |
| Book Value Per Share | $18.36 |
| Tangible Book Value | $1.00B |
| Tangible Book Per Share | $17.13 |
| Total Assets | $1.48B |
| Total Liabilities | $406.01M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $323.04M |
|---|---|
| FCF Per Share | $5.55 |
| Depreciation and Amortization | $22.83M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 22.17%, against a 5-year average of 27.96%.
| Gross Margin | 74.03% |
|---|---|
| Operating Margin | 22.17% |
| Pretax Margin | 23.55% |
| Net Margin | 18.05% |
| EBITDA Margin | 24.42% |
| Gross Margin (5Y Average) | 79.43% |
| Operating Margin (5Y Average) | 27.96% |
| Net Margin (5Y Average) | 22.71% |
Growth
Revenue grew 25.64% a year over 3 years, and EPS 5.89% a year.
| Revenue Growth (3Y CAGR) | +25.64% |
|---|---|
| Revenue Growth (5Y CAGR) | +40.30% |
| EPS Growth (3Y CAGR) | +5.89% |
| FCF Growth (3Y CAGR) | +34.09% |
| Operating Income Growth (3Y CAGR) | +20.15% |
| Book Value Per Share Growth (2Y CAGR) | +36.69% |
| Tangible Book Per Share Growth (2Y CAGR) | +54.05% |
Dividends and Yields
HRMY does not pay a dividend.
| Earnings Yield | 10.42% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 5 similar companies, HRMY has the 5th highest P/S.
P/S RatioPeer median 5.1x
ROICPeer median -28.99%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -51.69%
| P/S Ratio | 1.9x vs 5.1x median |
|---|---|
| ROIC | 13.73% vs -28.99% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +19.79% vs -51.69% median |
Analyst Forecast
Consensus estimates put revenue growth at 16.51% and EPS growth at 34.56% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +16.51% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +34.56% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HRMY
What is HRMY's market cap?
Harmony Biosciences Holdings has a market cap of $1.94B. Its enterprise value, which adds debt and subtracts cash, is $1.44B.
What is HRMY's P/E ratio?
Harmony Biosciences Holdings has a trailing P/E ratio of 9.6x and a forward P/E of 8.6x.
How many shares of HRMY are outstanding?
Harmony Biosciences Holdings has 58.41M shares outstanding. The count is up 1.49% from a year earlier.
Does HRMY pay a dividend?
No. Harmony Biosciences Holdings does not pay a dividend.
How much debt does HRMY have?
Harmony Biosciences Holdings has $149.10M of total debt and $647.10M of cash and equivalents, a net cash position of $498.00M.
HRMY pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts